Objective: To determine the frequency of older Americans with epilepsy receiving concomitant prescriptions for antiepileptic drugs (AEDs) and non-epilepsy drugs (NEDs) which could result in significant pharmacokinetic (PK) interaction, and to assess the contributions of racial/ethnic, socioeconomic, and demographic factors. Avoidance of interacting AEDs is feasible for most persons because of the availability of newer drugs.
drug combinations on the same biological target. Most PK interactions are related to hepatic processing, but can be related to absorption, protein transport, or renal clearance. Many AEDs are subject to these interactions. PK interactions among AEDs are well-known, but interactions between AEDs and other classes of drugs are less recognized. 1 Older AEDs are more likely to participate in PK interactions, especially the hepatic enzyme-inducing drugs phenytoin, carbamazepine, and the barbiturates. These drugs increase hepatic metabolism and decrease the effect of drugs metabolized by the same pathway. Conversely, valproate is often an enzyme inhibitor, raising the effective levels of other drugs. Newer AEDs, instead, are relatively free of PK interactions, as are drugs like topiramate and oxcarbazepine, which interact significantly only at high dosages. A set of guidelines published in 2007, Quality Indicators for Epilepsy Treatment (QUIET), includes this recommendation: "If newly diagnosed patients are taking medications for other disorders, then a physician should minimize the risk of interactions between newly prescribed AEDs and concomitant medications."
2 This is particular important among older adults for whom epilepsy is common, 3 and who are at high risk for drug interactions because they often take many drugs. Moreover, they are more vulnerable to toxic effects because of lower capacities for hepatic and renal drug elimination. 4 Many NEDs are critical for health, and small variations in effect may have serious consequences. Data on the extent of use of drug combinations subject to significant interactions among older Americans with epilepsy is limited. In our Quality of Epilepsy Treatment and Costs in Older Americans by Race (QUIET CARE) project, we examined quality care indicators for the Medicare population with epilepsy, focusing on differences in AED treatment by race/ ethnicity because of previous reports of treatment disparities. 5, 6 As part of this project, we examined the frequency and possible severity of interactions between AEDs and other commonly used drugs, and explored the concordance of epilepsy care with this QUIET indicator by race/ethnicity and by other demographic factors. We identified epilepsy prevalent cases using the following criteria for 2009 claims: (1) ≥1 claim (inpatient, outpatient, or physician visit) with International Classification of Diseases, version 9 (ICD-9) codes 345.xx (epilepsy), or ≥2 claims with 780.3x (seizures) at least 30 days apart, and (2) ≥1 prescription of 60 days or more for an AED. Similar definitions were found to have a positive predictive value of 94% for detecting cases of epilepsy among older veterans 7 and 70%-88% in a managed care population. 8 We defined the index date as the date of the first claim in 2009 that fulfilled the preceding criteria. To allow sufficient follow-up time to gather medication use data, we included only beneficiaries who had at least 1 year of follow-up after the index date with continuous Part A and B coverage and not on managed care plans, which feature closed panels of providers and restricted drug formularies and for which claims data are not available. Among these prevalent cases, we classified as incident those with continuous Medicare coverage for the year before the index date, and no claims with ICD-9 codes for epilepsy or seizures or any filled AED prescriptions during that year (1-year "clean" period).
| METHODS

Key Points
• One in 4 older Americans with incident epilepsy, and more than one-third with prevalent epilepsy, received an AED that could reduce the effect of the nonepilepsy drug
• Smaller proportions had drug combinations with evidence of high or medium risk of interaction
• One in 5 incident cases received a drug combination that could alter the effect of the AED and potentially cause toxicity
• Having interacting drug-pair combinations was more likely for those with comorbid conditions or eligible for a low-income subsidy, while having care from neurologists, being Asian, and living in the northeastern United States was protective
| Outcomes
Using Part D claims for prescription drugs, we determined the 50 most common NEDs prescribed to persons with epilepsy for which they had a prescription on the index date (ie, the epilepsy index date fell within the drug supply period). We then identified AED prescriptions filled within a window of AE60 days around the index date. The primary outcome event was the simultaneous presence of prescriptions for a combination of an AED and an NED with a risk for a PK interaction. We assessed risk for these AEDs: phenytoin, carbamazepine, phenobarbital, valproate, topiramate, and oxcarbazepine. We conducted a literature review to identify known interactions between these AEDs and the 50 most commonly prescribed NEDs in our population.
There is no definitive resource for drug interactions. Lists from reference sources often disagree. 9 We chose to use the U.S. listed in prescribing information. For the category "risk probable but unspecified," no published interaction data were found, but a likely interaction was suspected because of their known common metabolic pathway. For other pairs of AEDs and NEDs, interactions were either proven not to exist from the literature or highly unlikely because of dissimilar metabolic pathways. This list of drug combinations is necessarily subjective, but we believe that it is conservative and consistent with the available literature. We defined any risk as cases having high, medium, or probable but unspecified risk. Beneficiaries who had no prescriptions for drug combinations specified in Table 1 were considered to have no interaction risk. We also defined interaction risk for the NEDs altering the effect of AEDs: several NEDs inhibit the metabolism of AEDs, and a few increase the effect of AEDs (Table 1 ).
| Analysis
We estimated the overall and race-specific frequency of incident and prevalent cases having any, high, medium, or probable but unspecified interaction risk of AEDs on NEDs, and the frequency of cases having interaction risk of NED on AED efficacy. Logistic regression was used to model any risk, high risk, and the combination highmedium interaction risk of AEDs on NEDs, and risk of drug combinations that affect AED efficacy, with adjustment for covariates.
Covariates considered included the following: (1) individual factors-race/ethnicity, age at the index epilepsy event, gender, number of comorbid conditions, and source of epilepsy care; that is, having at least one claim for a visit with a neurologist or neurosurgeon in the time period from 45 days before to 60 days after the index date; (2) socioeconomic factors-eligibility for Part D Low Income Subsidy, ZIP (postal) code indicators of poverty; and (3) geography: U.S. residence region (Northeast, West, Midwest, or South). Number of comorbid conditions was identified in the year before the index event based on those included in the calculations of the Charlson Comorbidity score. 16, 17 ZIP code information on poverty was obtained from the 2010 Census. We created indicators for high poverty corresponding to ZIP code levels with >20% of households living below 100% of the Federal Poverty Line. All analyses were conducted with SAS version 9.4 (Cary, NC, USA).
3 | RESULTS
| Demographics
We identified 36 912 prevalent cases of epilepsy and 3706 incident cases (Table 2) . Prevalent and incident epilepsy cases were demographically similar. Among the incident cases, 64.9% were female, 18% were white, 61.2% African American, 12.3% Hispanic, 6.6% Asian, and 2.0% American Indian/Alaskan Native. By design, minorities were overrepresented (Table 2) . Most (72.8%) saw a neurologist close to the index date (versus only 36.3% of prevalent cases), and other health problems were common: 41% had 1-3 and, 55.3% 4 or more comorbid conditions. Many were poor: 77.2% qualified for the Part D Low Income Subsidy. About half resided in the South and 18.8% in the Northeast.
| Incident cases
A drug combination with high, medium, and probable but unspecified risk of interaction was present in 6.9%, 10.3%, and 18.5% of incident cases, respectively (Table 3) . A beneficiary could also have multiple interaction risks: for the total study population 75.5% had no interaction risk, and 24.5% were potentially at risk for some interaction (any risk). The proportion with any risk ranged from 30.4% for African Americans and 29.8% for AI/AN, to 21.5% for Asians. Moreover, 18% of incident cases, ranging from 18.7% of whites to 13.7% of Hispanics, also had drug interactions that increased the effect of the AED, whereas 2.4% had interactions that decreased the AED effect (Table 3 ).
| Prevalent cases
Among prevalent cases, 39% were taking a drug combination that could alter the efficacy of the NED (any risk) ( Table 3 ). The proportion ranged from 41.7% of Hispanics to 32.7% of Asians. Moreover, 26.2% of prevalent cases had potential interactions that could increase the effect of AEDs, ranging from 27.6% of African Americans to 19.9% of Asians, and 3% had interactions that could decrease AED efficacy. Table 4 lists NEDs, among the most common 50, that were prescribed to at least 5% of incident epilepsy cases and carry a documented or probable interaction risk with AEDs. Among cases taking each NED, Table 4 lists the percentage taking phenytoin and carbamazepine. Combinations with phenobarbital, valproate, topiramate, and oxcarbazepine are not reported due to low numbers. The most common NEDs were metoprolol and simvastatin, with about 25% of cases filling prescriptions for these drugs. Among cases on simvastatin, 30.9% had prescriptions for phenytoin corresponding to 7.6% having this probable but unspecified risk drug combination. Prescriptions for warfarin were filled by 11% of cases, of which 33.3% were also on phenytoin, corresponding to 3.6% having this highrisk drug combination.
| Specific interacting combinations among incident cases
| Relationship of interaction risk to demographic factors
In adjusted logistic regression models, factors associated with lower likelihood of any risk in the incident population were the following: (1) 
| DISCUSSION
Many older Americans receive AEDs, especially phenytoin, which are involved in PK interactions with drugs commonly used for the treatment of other conditions. 1 Almost one-fourth of our incident cases received at least one such combination. Moreover, 1 in 5 had a drug combination that altered the effect of the AED. The proportion of beneficiaries with interaction risk was higher among prevalent cases.
Our hypothesis that quality of care by this measure would vary markedly by race/ethnicity was not supported: we found only that Asian Americans were at slightly lower risk by some measures. A more important factor was income status: persons designated as low-income, because of eligibility for the Part D LIS, were more likely to have a high risk, or a high-medium risk drug combination. This individual measure of income status is likely more accurate than one measured at the ZIP code of residence: in fact, our measure of poverty at the ZIP code level was not associated with interaction risk. This finding calls into question studies that assess quality of care by race/ethnicity without controlling for income levels. In addition, we found that having more comorbid conditions was associated with a higher risk of having interacting drug combinations, while having care by a neurologist was associated with lower risk, suggesting the importance of specialty care. It is encouraging that prescribers seem to be more averse to prescribing high risk drug combinations than combinations we rated as either medium risk or probable but unspecified risk (Table 3) . However, the latter category does not necessarily imply low risk, just a risk not yet quantified in the literature. Overall, the problem of drug interactions with AEDs may be improving. The 24.5% proportion of older adults with new-onset seizures who started on medication during 2009 with interacting NED-AEDs was lower than the 39% found among the prevalent cases. Furthermore, it was lower than the 45.5% rate among new cases reported by Pugh et al. for an older veteran population treated from 1999 to 2004. 18 This is in line with a reduction in the prescription of older enzyme-inducing AEDs. In our incident population we found that about 44% were prescribed enzyme-inducing AEDs 19 compared to about 60% of a cohort of older veterans with new-onset seizures who began on medication in 2006. 20 Some drug interactions are quite dangerous and present immediate risk. It is reassuring that the combination of warfarin and phenytoin was used in only 3.6% of incident cases. The effect of phenytoin on warfarin is unpredictable and may vary over time, so either bleeding or clotting may ensue. Digoxin plus phenytoin was prescribed in 2.5% of incident cases: this combination could increase the risk of heart failure because phenytoin enhances hepatic elimination of digoxin. Finally, 2.4% were taking both quetiapine and phenytoin, where the reduced effect of quetiapine could cause decompensation of psychiatric conditions. Other risks accumulate over time-phenytoin increases both metoprolol and simvastatin metabolism, effects that could lead eventually to higher risks of vascular disease. 21 Most of these interactions involve reduction of the effect of the NED by simultaneous use of an enzyme-inducing AED. A few have the opposite effect: phenytoin and carbamazepine strongly inhibit metabolism of sertraline, a common antidepressant, which could cause adverse serotonergic effects. However, citalopram, another common antidepressant, has a diminished effect when taken with these AEDs. Thus the choice of antidepressant can be important in persons with epilepsy. 22 Drug interactions are frequently predictable. We chose to list as probable but not specified those combinations that share metabolic pathways, even when no primary literature quantifying the interaction was found. Thus drug pairs sharing the cytochrome P 450 (CYP)3A4 pathway, such as carbamazepine and escitalopram, are included in our list. As new drugs are introduced to the market, such interactions can be predicted, and warnings should be placed in product information and electronic references. For existing drugs, many electronic medical record systems generate warnings when interacting combinations are prescribed, but these warnings can be overridden. Sometimes this is necessary because it is medically appropriate to prescribe the interacting pair, but there may be better alternatives. There is no evidence that the older, interacting AEDs are more effective in general populations 23 or in older persons, 24 so there is no efficacy advantage to starting with one of these older drugs.
There are limitations to our study. First, any list of drug interactions and any qualitative ranking of their potential severity reflects the judgment of the authors. Second, we measured only concomitant use of the 50 most-often prescribed NEDs for this Medicare population. There are thousands of other drugs that could interact with AEDs. AEDs may participate in serious interactions with important classes of drugs that are not among the 50 most common NEDs prescribed to our Medicare cohort. These critical drugs include antivirals and antineoplastic agents. Thus our numbers should be considered low estimates. Our goal was not to identify all possible drug interactions with AEDs, but to get a sense of the magnitude of the problem for older persons of different races and demographic descriptions. Third, we did not assess interactions among AEDs, which are numerous and quantitatively significant. However, in our cohort of incident cases, less than onefourth had more than one AED in the follow-up period. 25 Fourth, we did not evaluate pharmacodynamic interactions, which are common but difficult to quantify. Fifth, the number of comorbidities may be underestimated because we did not identify psychiatric conditions, although psychiatric drugs are included in our analyses. Consequently, we may have not accurately estimated the effect of this number on the likelihood of interaction risk, and if different across demographic groups, we may have not appropriately adjusted for confounding of the association between demographics and interaction risk. Sixth, our study included only older Medicare recipients enrolled with Part D prescription plans. Medicare beneficiaries with other or no drug coverage were not included in our sample. We should emphasize that our study population was not intended to be representative of the entire older Medicare population because we oversampled minority groups. However, because we found only small differences across racial groups, we believe that our results are likely applicable to the general population of older persons.
In conclusion, in this population of older Americans, one in 4 with new-onset epilepsy may have received care that did not "minimize the risk of interactions between newly prescribed AEDs and concomitant medications" in line with QUIET indicators. However, fewer were receiving drug combinations that have evidence of high or medium risk of interaction. Most newer AEDs are less likely to be involved with PK interactions, and, therefore, may be more appropriate choices for older persons. 26 If use of an interacting AED is unavoidable, careful monitoring for side effects is necessary and, in some cases, serum drug level measurements of the NED or AED may be needed. Warnings built into electronic prescribing programs and provider education may mitigate this problem. Referral to specialty care with a neurologist or epilepsy specialist to address the complexities of treatment of older adults with epilepsy may be desirable.
